Arming Our Enemies: How Parallel Imports Could Increase Antimicrobial Resistance by Crossman, Colin Robert
NORTH CAROLINA JOURNAL OF
INTERNATIONAL LAW AND
COMMERCIAL REGULATION
Volume 31 | Number 4 Article 1
Summer 2006
Arming Our Enemies: How Parallel Imports Could
Increase Antimicrobial Resistance
Colin Robert Crossman
Follow this and additional works at: http://scholarship.law.unc.edu/ncilj
This Article is brought to you for free and open access by Carolina Law Scholarship Repository. It has been accepted for inclusion in North Carolina
Journal of International Law and Commercial Regulation by an authorized editor of Carolina Law Scholarship Repository. For more information,
please contact law_repository@unc.edu.
Recommended Citation
Colin R. Crossman, Arming Our Enemies: How Parallel Imports Could Increase Antimicrobial Resistance, 31 N.C. J. Int'l L. & Com. Reg.
823 (2005).
Available at: http://scholarship.law.unc.edu/ncilj/vol31/iss4/1
Arming Our Enemies: How Parallel Imports Could Increase Antimicrobial
Resistance
Cover Page Footnote
International Law; Commercial Law; Law
This article is available in North Carolina Journal of International Law and Commercial Regulation: http://scholarship.law.unc.edu/
ncilj/vol31/iss4/1
Arming Our Enemies: How Parallel Imports Could
Increase Antimicrobial Resistance
Colin Robert Crossmant
I. Introduction ....................................................................... 823
II. Biology of A ntibiotics ....................................................... 824
A . The First A ntibiotic ..................................................... 824
B. The Evolution of Resistance ....................................... 826
C. Manifestations of Resistance ...................................... 829
D. Combating Resistance ................................................. 831
III. Implications of the Economics of Parallel Imports and
Drug Subsidization on Antibiotic Resistance .................... 833
A . B ackground ................................................................. 833
B . Parallel Im ports ........................................................... 835
C. Drug Subsidization Measures ..................................... 837
D . C onsequences .............................................................. 837
1. Research Effects .................................................... 838
2. Effects of M isuse ................................................... 839
a. Unnecessary Consumption ............................... 840
b. Underconsumption ................... 844
IV . C onclusion ......................................................................... 844
I. Introduction
In response to the high prices of pharmaceuticals, both in the
developed world and the developing world, politicians, advocacy
groups, and consumers have rallied around parallel imports as a
way of reducing the prices of cutting-edge medicines. However,
these policies, price reductions, and the concurrent rise in
consumption inherent thereto may present a new problem for the
class of pharmaceuticals most needed to prevent morbidity and
mortality: antimicrobials.
Antimicrobial drugs, particularly antibiotics and antivirals, are
susceptible to obsolescence by overuse. This happens when the
t The author would like to thank Arti Rai, Catherine Admay, Deanna Carrick,
Lauren Dame and Ilse Weichers, all from Duke University, for their assistance and
motivation throughout the production of this paper.
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target of the antimicrobial drug develops resistance, a process that
can occur with alarming rapidity. The speed with which microbial
strains develop resistance can be controlled somewhat with proper
use, whereas abuse can dramatically increase the rise of resistance.
This paper discusses the rise of resistant strains of microbes as
a consequence of improper use and presents examples from both
the developed and the developing world. It then presents the
economic consequences of parallel imports, and places those
consequences in context with the problem of microbial resistance.
Finally, it discusses potential solutions to the problem, and
reconciles those solutions with the policies of parallel imports.
II. Biology of Antibiotics
A. The First Antibiotic
The search for compounds which could kill infectious agents
dates back to the late nineteenth century.' Several compounds
were indeed discovered, but each one possessed fatal flaws, and
fell short of the "magic bullet" needed; they were excessively
toxic to humans and their antibiotic effects were unpredictable.2
Penicillin, the first truly safe antibiotic agent, was discovered
by Sir Alexander Fleming in 1928.' A typical story of scientific
serendipity occurred while Fleming was studying components of
human tears.4 He had just returned from a vacation, and noticed
that several unwashed bacteria plates had been left in his work
area.5 On one of the plates, he noticed that a mold had taken root,
and a clear halo-indicative of massive bacterial death-was
present around the mold.6
I STUART B. LEVY, THE ANTIBIOTIC PARADOX: HOW THE MISUSE OF ANTIBIOTICS
DESTROYS THEIR CURATIVE POWERS 32 (2d ed. 2000).
2 See id. at 35-36. Pyocyanase and Salvarsan were two such compounds
discovered in 1888 and 1910 respectively. Pyocyanase was toxic, difficult to administer,
and did not have a long shelf life. Salvarsan, in contrast, was stable, but contained
arsenic, and had extremely toxic side effects. Id. at 35-36.
3 See generally Penicillin's Finder Assays its Future: Sir Alexander Fleming Says
Improved Dosage Method is Needed to Extend Use, N.Y. TIMES, June 26, 1945.
4 See LEVY, supra note 1, at 37.
5 Id.
6 Id.
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Fleming tested the phenomenon, and discovered that the mold
produced a compound that was directly responsible for the
bacterial death he observed.7  In honor of the mold's name,
Penicillium notatum, he called the compound penicillin.8 Fleming
was unable to isolate large quantities of penicillin from the mold,
however, and so was unable to test the compound in any animals.9
It was not until the late 1930s that large quantities of penicillin
began to be synthesized, tested, and eventually made available to
the military.' ° In 1942, penicillin was made available to some
members of the public and in 1944 to the general public."
In 1945, Fleming, who had become a minor celebrity due to
his discovery, was interviewed by the New York Times. 12 In that
interview, he expressed concern about the result of converting
penicillin into an oral drug, which would allow for easy access by
the public and potentially allow the creation of resistant strains. 13
Fleming observed some resistance, albeit in controlled settings,
when initially experimenting with penicillin, even though he had
limited access to the compound. 14  By 1946, scientists observed
the first clinical cases of penicillin resistance, the beginnings of
wide-spread resistance to penicillin. 15
7 Id. at 38.
8 Id.
9 Id. at44.
10 See LEVY, supra note 1, at 43-44.
11 On November 29, 1942, the Cocoanut Grove, a Boston, Massachusetts bar, was
the scene of a horrible fire. Several hundred people were killed and many survivors were
severely burned. At the time, the prognosis for bum victims was grim, as infections
routinely took advantage of easy access and weakened bodies. The Cocoanut Grove
victims were different, however. The United States Government released a substantial
quantity of penicillin to the victims and in what was the largest clinical trial of the
compound, nearly every patient treated with the penicillin avoided infection. Id. at 1-7.
12 Penicillin's Finder Assays its Future: Sir Alexander Fleming Says Improved
Dosage Method Is Needed to Extend Use, N.Y. TIMES, June 26, 1945, at 21.
13 Id. ("The greatest possibility of evil in self-medication is the use of too-small
doses, so that, instead of clearing up the infection, the microbes are educated to resist
penicillin and a host of penicillin-fast organisms is bred out which can be passed on to
other individuals and perhaps from there to others until they reach someone who gets a
septicemia or a pneumonia which penicillin cannot save.")
14 LEVY, supra note 1, at 7-8.
15 Id.at 11. Stephen R. Palumbi, Humans as the World's Greatest Evolutionary
Force, 293 SCIENCE 1786 (2001) (indicating that up to fifty percent of bacterial agents
N.C. J. INT'L L. & COM. REG.
B. The Evolution of Resistance
According to Dawkins, "[l]ife results from the non-random
survival of randomly varying replicators."'16  Resistance to
antimicrobials is a result of such evolution.17 Given a sufficient
amount of time and a large enough population, a particular life-
form will find some way to adapt to a particular environmental
stimulus.18
Traditional theory, such as that stated by Dawkins, holds that
this adaptation occurs as a result of natural variation.19 The natural
variation arises due to the incidence of errors in the genetic
material of the organism.2" Though environmental factors, such as
radiation and chemical exposure, are known to cause genetic
damage-and hence errors-they play only a small role in the
creation of errors in microorganisms. 2' The vast majority of the
errors in their genetic material are caused by the microorganisms
themselves, due to sloppy copying.22
When any cell replicates, it must generate a total copy of its
genetic material.23 The machinery that does the copying is
tremendously precise, and includes substantial error checking
processes, as too many errors may cause the death of the daughter
cells.24 However, occasionally a mistake is made, and any such
like Staphylococcus aureus are penicillin-resistant).
16 ARTHUR MCGRATH, DAWKINS' GOD: GENES, MEMES, AND THE MEANING OF LIFE,
37 (2005) (summarizing RICHARD DAWKINS, THE BLIND WATCHMAKER 128-37 (1996),
"evolution can ...be seen as the outcome of the non-random survival of randomly
varying replicators."). Dawkins didn't use this formulation anywhere (Google print
search for: Dawkins "Nonrandom survival").
17 See generally Palumbi, supra note 15, at 1786 (discussing the causes and
impacts of human-induced microbial evolution).
18 See MCGRATH, supra note 16, at 315-18.
19 Id.
20 Id.
21 Id.
22 See Alan R. Fersht & J. W. Knill-Jones, DNA Polymerase Accuracy And
Spontaneous Mutation Rates: Frequencies Of Purine Purine, Purine Pyrimidine, and
Pyrimidine'Pyrimidine Mismatches During DNA Replication, 78(7) PROC. NAT'L. ACAD.
SCI. USA 4251, 4251-55 (1981).
23 BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 21 (4th ed. 2002).
24 See id. at 235-36 (explaining the replication mechanisms of Escheridia coli and
certain mammals).
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errors are passed to the daughter cells.25  The errors that survive
the error checking process become part of the inherent variation of
the species.26
When presented with selective pressure, the effects of the
errors become apparent. Some errors may be deleterious-under
selective pressure, the organisms which possess such errors will
die off at an increased rate. 7 Other errors may be advantageous,
allowing a particular organism to survive when its unlucky
brethren die off more quickly. 28 In this way, the organisms which
possess traits allowing them to cope with the selective pressure
begin to compose a greater percentage of the population.
Essentially, those organisms, and their progeny, are able to
reproduce-and avoid dying-at higher rates than other
organisms. This effect is made more prominent as the penalty for
not possessing a trait is increased.29
Thus far, this article has addressed only classical theory.
There are several complicating factors that radically increase the
ability of organisms to discover and incorporate advantageous
traits.
In some instances, microorganisms presented with a selective
pressure can "intentionally" increase their genetic error rate.3° In
25 As an example, the error rate for Pfu DNA Polymerase is generally on the order
of lxi0 -6 errors per base pair. That means that for every I million base pairs copied,
there will be only one error. See Stratagene.com, FAQ: What is the Error Rate for Pfu
DNA Polymerase?, http://www.stratagene.com/lit/faq/faq.aspx?fqid=149. In actual in
vivo systems, the error rate is closer to lxl0 "9. See ALBERTS ET AL., supra note 23, at
236.
26 See ALBERTS ET AL., supra note 23, at 237.
27 Id. at 236-37.
28 The definitions of "advantageous" and "disadvantageous" with respect to genetic
errors do not imply some sort of objective standard. Such terms are only meant to imply
survivability relative to the currently considered selective pressure. Indeed, what may be
advantageous in one context may be highly disadvantageous in other contexts. Take, for
example, the Pekinese dog breed. The breed was bred to emphasize features attractive to
certain humans. Those very features-snub nose, conspicuous lack of biting teeth, small
body size-would convey a tremendous disadvantage in the wild. The Pekinese,
however, is precisely designed for its role as a lap dog.
29 Antibiotics and other antimicrobials represent the ultimate selective pressure.
All organisms, which do not possess a solution to the selective pressure, die. See
MCGRATH, supra note 16, at 178-79.
30 See, e.g., Bryn A. Bridges, Hypermutation in Bacteria and Other Cellular
Systems, 356 (1405) PHIL. TRANSACTIONS: BIOLOGICAL SC. 29-39 (2001) (describing
N.C. J. INT'L L. & COM. REG.
these cases, when a selective pressure is applied, the
microorganisms increase their error rate, which consequently
increases their ability to find errors which effectively
neutralize the selective pressure. Though this is a tool for most
bacteria, for some viruses, it is a standard condition. Human
Immunodeficiency Virus (HIV), by its nature as a retrovirus,
incorporates a tremendous number of errors in its genetic
material.31
In other instances, microorganisms can share their successful
traits with other microorganisms. 32 Though they possess only one
genome, they also often possess subgenomic strands of DNA
called plasmids which also may confer traits.33 These plasmids
can be passed back and forth between microorganisms.34
Sometimes, a plasmid confers a trait which directly influences a
microorganism's ability to survive, and often that trait is an
antibiotic resistance of some sort.3
Microorganisms can occasionally absorb genetic material from
their surrounding environment. 36 Even if selective pressure causes
a disproportionate number of sensitive microorganisms to perish,
some resistant organisms will also inevitably die. If a trait which
confers resistance is transferable, it is possible that a sensitive
organism will absorb some errant genetic material from the
resistant organism and "learn" resistance, regardless of the
differentiation between the species.37
Finally, certain microorganisms possess special constructs that
transient mutator states occurring in cells as a result of stress); Erin K. O'Reilly &
Kenneth N. Kreuzer, Isolation of SOS constitutive mutants in Escherichia coli, 186(21) J.
BACTERIOLOGY 1749, 1758-60 (2004) (describing endogenous sources of DNA damage
in Escherichia coli).
31 See John D. Roberts et al., The Accuracy of Reverse Transcriptase From HIV-J,
242 SCIENCE 1171, 1172 (1988). Reverse transcriptase, especially the reverse
transcriptase of HIV, is highly error-prone. HIV's reverse transcriptase has an error rate
of one in 2000, or three orders of magnitude more error-prone than other polymerases.
Id.
32 See generally LEVY, supra note 1, at 71-114.
33 See id. at 72.
34 See id. at 82-88.
35 See id. at 72-74.
36 See id. at 79.
37 See id. at 88-93.
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allow them to alter their own genetic code in particular ways. For
instance, the influenza virus periodically reshuffles parts of its
genetic material, to generate resistance to our immune systems.38
This reshuffling results in slightly different surface proteins, and
therefore a different outward appearance.3 9 In other contexts, an
organism may activate/deactivate their resistances as needed.4 °
C. Manifestations of Resistance
Using all the tools of evolution and transformation discussed
above, microbes routinely learn a variety of methods to defeat
antimicrobial drugs. These methods fall into one of two essential
categories; microbes can defeat antimicrobial drugs by either
destroying them or avoiding them.4'
In a very few instances, the microbes learn ways to destroy
the drug.42 The microbes generate proteins which speed the
degradation of the drug so rapidly that the drug does not have
much chance to adversely affect the organism. 43 In some cases,
depending on the efficiency of the degradation mechanism,
increased doses of the drug may continue to provide therapeutic
benefit. 44 However, eventually the increased doses will engage the
same selection machinery, causing the organism to adapt again.
Penicillins, cephalosporins, and streptomycins all fall victim to
drug-destroying processes.45
38 This is why influenza vaccines must be administered every year, and why the
vaccine manufacturers attempt to predict the next transition of the influenza virus. John
Treanor, Influenza Vaccine-Outmaneuvering Antigenic Shift and Drift, 350(3) NEW
ENG. J. MED. 209, 218-20 (2004).
39 This is like a criminal having plastic surgery to avoid detection by the
authorities. Id.
40 See Milagro Reig et al., Inducible Expression of Ribosomal Clindamycin
Resistance in Bacteroides vulgatus, 36 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
639, 639 (1992).
41 See LEVY, supra note 1, at 96.
42 See id. at 98-99.
43 Id. at 98.
44 See, e.g., Keith P. Klugman & Thora Capper, Concentration-dependent Killing
of Antibiotic-resistant Pneumococci by the Methoxyquinolone Moxifloxacin, 40(6) J.
ANTIMICROBIAL CHEMOTHERAPY 749, 797-802 (1997) (describing how differing
concentrations of antibiotics can still affect resistant strains of pneumococci).
45 See LEVY, supra note 1, at 97-102.
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Avoidance measures are more varied, but they all accomplish
the same purpose-they lessen or eliminate the ability of the
antimicrobial drug to affect the microbe.46 In some cases, the
microbe engages mechanisms to minimize absorption of the drug,
such as pumping the drug out of the microbe or blocking entry.47
Other avoidance measures involve the microbe altering the target
proteins in such a way as to render the antimicrobial drug
impotent.48
In some ways, avoidance measures are more worrisome than
measures which eliminate the drugs.49 Many of these drugs are
capable of persisting in nature for long periods of time; the
environmental presence of antimicrobials will contribute to the
emergence of resistant strains, as the drugs exert a selective
pressure."0
Though the prospect of antimicrobial resistance is disturbing,
the ability of viruses, fungi, and eukaryotic parasites to effectively
develop resistance to treatment compounds is just as troubling.
For instance, HIV replicates so rapidly that the virus can
effectively find resistance to such treatment compounds during the
course of treatment in a particular individual.5 Indeed, the virus is
so adept at working around treatments that more exotic treatment
strategies utilizing several simultaneous, non-overlapping modes
of attack is now the standard protocol. Malaria treatments, such as
quinine and chloroquine, have also met a similar fate.52
46 Id. at 97.
47 Id. at 99.
48 See generally id. at 102 (discussing the fact that many antibiotics persist in the
environment killing off susceptible bacteria in the natural systems and leaving only the
resistant bacteria to survive).
49 Id. at 102; see also Shunwoo Yang & Kenneth Carlson, Routine Monitoring of
Antibiotics in Water and Wastewater with a Radioimmunoassay Technique, 38 WATER
RES. 3155, 3156 (2004).
50 See Yang & Carlson, supra note 49, at 3156.
51 See, e.g., Barbara A. Backlaws, Quantification of the Reservoir of HIV-1, 5(6)
TRENDS MICROBIOL 215 (1997) (showing the quantization of viral load in follicular
dendritic cells is 1.5 x IOA8); Mark Dubyl et al., Guidelines for Using Antiretroviral
Agents Among HIV-Infected Adults and Adolescents: The Panel for Clinical Practices
for Treatment of HIV, 137(5.2) ANNALS INT. MED. 381, 381-433 (2002); M. Piatak, et al.,
High Levels of HIV-1 In All Stages of Infection Determined by Competative PCR,
259(5102) SCIENCE 1749 (1993).
52 See J. Kevin Baird, Effectiveness of Antimalarial Drugs, 352 NEw ENG. J. MED.
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Viral resistance is not restricted to the blight of HlV. The
current avian influenza, H5N1, has already shown resistance to the
most capable preventative measure: Tamiflu. 53  Furthermore,
ninety-one percent of the 2005-2006 human influenza strain,
Influenza H3N2, show resistance to both amantadine and
rimantadine, two older anti-influenza drugs.54 Though the H5N1
avian influenza virus has shown only limited ability to infect
humans, it has caused a tremendous frenzy about the potential for
a new pandemic.55  Though such fears have, as yet, been
unrealized, the virus may eventually mutate to a strain which is
human-communicable.56 That eventuality would be all the more
deadly if the only compound known to provide succor is useless.57
Indeed, the fear of an epidemic has itself resulted in Roche, the
manufacturer of Tamiflu, massively increasing production, and
allowing some degree of ad-hoc parallel imports.58
D. Combating Resistance
The occurrence of resistance is the natural result of the
1565, 1569-72 (2005). Quinine was discovered to have anti-malarial qualities in the
mid-eighteenth century. Id. It has been so widely dispersed that today it is even
available over the counter as an ingredient of Tonic Water. During World War II,
chloroquine was developed as an alternative to quinine. By 1957, chloroquine resistance
was seen in Asia, and is now globally prevalent. Id. For unknown reasons, quinine
remains effective against most malaria, however quinine-resistance strains have recently
been discovered. Id.
53 See Menno D. de Jong, et. al, Oseltamivir Resistance during Treatment of
Influenza A (H5N1) Infection, 353 NEw ENG. J. MED. 2667, 2667 (2005). Two
Vietnamese girls who were given Tamiflu prophylaxis developed Tamiflu resistant
H5NI (avian flu). Fortunately, the avian flu has not yet become a human contagion, and
so the particular resistant strain will not likely spread. Tamiflu resistance is believed to
be the result of a single point mutation in the virus. If true, this makes the likelihood that
tamiflu sensitive strains will.
54 Lawrence K. Altman, This Season's Flu Virus is Resistant to 2 Standard Drugs,
N.Y. TIMES, Jan. 15, 2006, at Sec. 1.
55 Olivia Judson, Evolution Is in the Air, N.Y. TIMES, Nov. 6, 2005, at Section 4.
56 Tim Appenzeller, Tracking the next Killer Flu, NAT'L GEOGRAPHIC, Oct. 1,
2005, at 2-31.
57 See Graeme Laver and Elspeth Garman, The Origin and Control of Pandemic
Influenza, 293 SCIENCE 1776, 1776-77 (2001).
58 See Tom Wright, Roche Plans Big Increase in Tamiflu Production, N.Y. TIMES,
Nov. 10, 2005, at C6; see also Bloomberg News, Roche Tells Indonesia that it Can
Produce Tamiflu Without a License, N.Y. TIMES, Nov. 26, 2005, at C3.
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intersection of the forces of evolution with medical science. At
best, medicine can only delay the inevitable resistance through
designing novel therapies.
While proper therapeutic use will inevitably lead to resistance,
two activities radically increase the speed with which the microbes
can evolve solutions to a compound. The first problem is
unnecessary use of the compound; the second is under-use or sub-
therapeutic dosing for an indicated use.5 9 When compounds are
improperly used in these ways, selection pressures are generated,
but the therapeutic outcomes are either unrelated to the use of the
compound, or are insufficiently complete. In addition, excessive
and improper use of antibiotics can make diagnosis of other
conditions more difficult.6 °
Unnecessary use of an antimicrobial occurs when the
compound is administered to treat a condition for which the
compound is wholly unsuited or is genuinely irrelevant.6' Partly
due to the astounding success that antimicrobials have had and
partly due to the fact that most people simply don't understand
disease processes, there has been a huge number of doses used in
this way.62  Patients demand antibiotics to treat non-bacterial
infections, such as the common cold; some even demand
antibiotics for prophylaxis, when such prophylaxis is totally
unnecessary.63
The tendency of patients to consume sub-therapeutic doses,
partial courses, or to under-use the antimicrobials is problematic.
6 4
Antimicrobial under-use is a thornier problem than simple misuse.
In the under-use scenario, the initial condition did indeed warrant
the use of the particular antimicrobial consumed.65 However the
59 See LEVY, supra note 1, at 115, 124.
60 See, e.g., Calvin M. Kunin & Yung-Ching Liu, Excessive Use of Antibiotics in
the Community Associated with Delayed Admission and Masked Diagnosis of Infectious
Diseases, 35(3) J. MICROBIOL. IMMUNOL. INFECT. 141 (2002).
61 See LEVY, supra note 1, at 117.
62 Id. at 124.
63 See, e.g., Jerry Avorn & Daniel H. Solomon, Cultural and Economic Factors
That (Mis)Shape Antibiotic Use: The Nonpharmacologic Basis of Therapeutics, 133(2)
ANN. INTERN. MED. 128, 135 (2000).
64 See LEVY, supra note 1, at 289.
65 Id. at 290.
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patient either ceased using it prior to taking a full course of the
drug, or the patient was not taking a sufficient dose of the drug.
66
One of the most common reasons for under-use to occur is that
patients stop taking the antimicrobial when they feel better.67
Unfortunately, the remaining, neglected doses would have helped
to thoroughly cleanse the body of the microbe. The microbes that
remain have an increased likelihood of discovering resistance,
since they have been exposed to the compound, but not killed by
it.68
III. Implications of the Economics of Parallel Imports and
Drug Subsidization on Antibiotic Resistance
A. Background
The rising price of drugs is of perennial and growing concern
for health care providers and policy makers. 69  High drug prices
limit access to medicines, and have the tendency to leave the
poorest untreated and suffering.70 These prices are especially
egregious considering that the actual production cost for most
drugs is relatively trivial.7
The main expense in drug production is not the cost of
manufacturing approved drugs, but rather the costs associated with
drug discovery: research, development, and clinical trials.7" These
66 Id.
67 See Cipro Package Insert, http://www.univgraph.com/bayer/INSERTS/CIPRO
TAB.pdf. This is exacerbated by the fact that antimicrobials, especially more modem
ones like ciprofloxacin (Cipro), can cause several unpleasant and annoying side effects.
Id. Cipro, for instance, often causes hypersensitivity to sunlight, diarrhea, and nausea,
and has adverse interactions with dairy, antacids, caffeine, and alcohol. Id.
68 See LEVY, supra note 1, at 292.
69 See, e.g., States News Service, Patent Bill Splits the Drug Industry, N.Y. TIMES,
Aug. 15, 1982, Sec. 11, at 4. See also Editorial, Pricing Drugs, WASH. POST, Feb. 17,
2004, at A18; Kim Kahn, Merck CEO Gilmartin Says All Must Contribute to Lower Cost
for Developing Nations, CNN MONEY, Feb. 2, 2002, http://money.cnn.com/2002/02/02/
news/davosdrugs/.
70 See Kahn, supra note 69.
71 See Ernst R. Berndt et al., Information, Marketing, and Pricing in the US
Antiulcer Drug Market, 85(2) AM. ECON. REV. 100 (1995). Actual manufacturing costs
will vary by drug, but have been reported to be as low as ten percent of the sales price.
Id.
72 Joseph A. DiMasi et al., The Price of Innovation: New Estimates of Drug
N.C. J. INT'L L. & COM. REG.
discovery costs are so high that recouping the costs through the
marketplace would be nearly impossible if competitors are
allowed to begin producing the product immediately.
In order to solve this problem, drug researchers are granted
patents over their discoveries, which temporarily provides them
certain exclusive rights to their discoveries.73 By granting the
discoverer a limited monopoly, the discoverer can manipulate that
monopoly to provide a sufficient return to recoup the costs
inherent in the discovery.74 Drug manufacturers, of course, seek
patents in every jurisdiction that they deem important to their
markets-giving them similar exclusive rights around the world.
The ability of the drug manufacturers to control prices,
however, is incomplete. Unless the drug is truly novel, and
addresses a disease previously uncontrollable, it is likely that there
are several drugs that already exist that are capable of providing
some relief.75 Even if a drug has the advantage of having no
substitutes, it must still compete with a patient's decision to forgo
the treatment.
Patents also give their holders the ability to engage in market
segmentation and price discrimination.76 By placing the ability to
Development Costs, 22 J. HEALTH ECON. 151, 152 (2003).
73 The exclusive rights are: making, using, offering to sell, selling or importing into
the United States. See 35 U.S.C. §217(a) (2005).
74 The Pharmaceutical industry spends, on average, fifteen years bringing a new
drug to market. This research and development includes searching for and testing
compounds, and also the clinical trials which test the promising compounds for safety
and efficacy. See Prafulla Joglekar & Morton Paterson, A Closer Look at the Risks and
Returns of Pharmaceutical R&D, 5(2) J. HEALTH ECON. 153 (1986). But see Michael S.
Wilkes et al., Direct-to-Consumer Prescription Drug Advertising: Trends, Impact, and
Implications, 19(2) HEALTH AFF. 110 (2000).
75 For example, Viagra, the first erectile dysfunction medication, was the first drug
that was found which could address the condition. Contrast Viagra with a novel
painkiller. Though the painkiller may provide significant benefits over existing
painkillers, it will be in competition with them. Additionally, if a drug is the first to
address a specific problem, it is likely that follow-on drugs will arise that take advantage
of other aspects of the treated condition to achieve similar results, perhaps even with
better clinical profiles. See generally Silvio Garattini, Are Me-Too Drugs Justified?,
10(6) J NEPHROLOGY 283-94 (1997).
76 See Kevin Outterson, Pharmaceutical Arbitrage: Balancing Access and
Innovation in International Prescription Drug Markets, 5 YALE J. HEALTH POL'Y, L. &
ETHICS 193, 193-286 (2005); Kristina M. Lybecker, Parallel Imports or Imposters: The
Economics of Reimportation and Counterfeit Pharmaceuticals, 16(3) J. PHARM'CAL
[Vol. 3 1
2006] PARALLEL IMPORTS AND ANTIMICROBIAL RESISTANCE 835
regulate imports of the patent-holder, even one patent gives the
patent-holder the power to segment the world market between the
nation covered by the patent, and the rest of the world. In this
simple example, the patent-holder could keep prices high in one
market, while competing on price in all others.
When the patent-holder has access to several patents, it can
potentially carve the world up into many independent markets, and
cover all economically significant nations and regions. Based on
the ability of the populace in each market to afford the product, the
patent-holder can charge whatever price will maximize profit.
Normally, in a situation analogous to water finding its own level, a
lower price in one region will stimulate arbitrage whereby
consumers in a higher price region purchase the product from
suppliers in the lower price region.77 However, the patent right
allows the patent-holder to wall off the different regions and
prevent arbitrage.
In the world of pharmaceuticals, even though drug-makers
may possess patents allowing them to price the drugs at monopoly
prices, in practice drugs tend to be fairly inexpensive in some
markets that could support much higher prices. For instance, in
2003, a basket of the thirty most prescribed medicines cost up to
fifty percent less in Canada, the United Kingdom and France, than
the United States.78 These price differentials are related to several
diverse factors, including price controls, bulk purchasing power
exercised by various national health care systems, stronger legal
tools for compulsory licensing, differentials in purchasing power,
and societal differences with regard to health care.7 9
B. Parallel Imports
Parallel imports, or gray-market goods, are imported copies of
a product protected by some class of intellectual property, which
are legitimately and legally purchased in a foreign jurisdiction.8 °
MKT'G & MGMT. 81, 81-100 (2004).
77 Id.
78 Gerard F. Anderson et al., Doughnut Holes and Price Controls, HEALTH AFF.
WEB EXCLUSIVE W4-397 (July 2004).
79 See Outterson, supra note 76, at 195.
80 Parallel imported goods are not restricted to patented goods, but rather any good
protected in any realm of intellectual property can be the subject of parallel imports.
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This activity is, obviously, in direct conflict with the patent
holder's exclusive right to control imports. In the United States,
the responsibility to restrict and regulate parallel imports rests with
the Department of Homeland Security, Immigration and Customs
Enforcement.81
The goal of parallel imports is to allow purchasers of a
protected good to obtain the good at the lowest price globally
available.82 With respect to the United States, consumers would
presumably be able to take advantage of the purchasing powers
and legal restrictions other countries have, to avoid some of the
patent premium which exists domestically. With respect to
developing nations, consumers and health boards would be able to
purchase the goods at the lowest global prices, without worrying
about the patent-holder restricting imports.
In the short term, this policy may benefit consumers in the
United States. It is hard to see how the developing world would
benefit, however, as the prices they may have to pay, which may
already be above their ability to pay, could rise even higher.83
This rise in prices could stem from manufacturers refusing to
supply smaller, less prosperous economies, for fear of driving
down prices elsewhere, or from outside buyers bidding up the
limited supply that is provided to such markets.84
Another complication caused by parallel imports is the
potential diminution in drug research and development. Since
private drug research and development is funded in large part by
the monopoly revenue extracted from the sales of currently
protected products, working to diminish that monopoly revenue
will necessarily lower the funds available for new drug
discovery.86  Several methods have been suggested to avoid or
remedy this problem, including transferring the responsibility for
81 19 U.S.C. §1337 (2005); 19 C.F.R. §0.1 (2005).
82 Keith E. Maskus, Final Report to World Intellectual Property Organization,
Parallel Imports in Pharmaceuticals: Implications for Competition and Prices in
Developing Countries 41 (Apr. 2001), http://www.wipo.int/about-
ip/en/studies/pdf/ssa-maskus-pi.pdf.
83 Id.
84 Solutions to this may include, perhaps, export restrictions limiting the parallel
trade leaving disadvantaged nations.
85 See Maskus, supra note 82, at 41.
86 Id.
[Vol. 31
2006] PARALLEL IMPORTS AND ANTIMICROBIAL RESISTANCE 837
research funding to the public sector, requiring all drug
manufacturers to pay into a research and development fund, and
increasing the drug patent term.
C. Drug Subsidization Measures
Drug subsidization measures include any program, measure, or
device by which the true cost of drugs, as charged by the supplier,
is shielded from the consumer. Drug subsidization, unlike parallel
imports, is generally directed only toward the poor, and may,
through bulk purchasing, be directed toward developing countries.
One of the most visible programs of drug subsidization for
developing countries is the subsidization of AIDS drugs.88
D. Consequences
Though they take advantage of differing methods, both parallel
imports and drug subsidies function by lowering the cost of drugs
to consumers. By holding drug prices at a lower level, it is hoped
that people with less means will have the opportunity to share in
the technological advances that medical research has brought to
the marketplace. For many drugs, lowering the price is unlikely to
present significant unforeseen consequences for the drugs
themselves. As mentioned above, the impacts on drug research,
though present, may be manageable by creative research funding.
What has previously been neglected is the impact that policies
which lower prices, such as those embracing parallel imports and
drug subsidies, will have on antimicrobial resistance. Measures
such as parallel imports, which seek to increase access and lower
price, will have the effect of increasing consumption of affected
drugs.89 With most drugs, this is of little concern, and is indeed
desired. Except where the consumption of a drug leads to some
87 See, e.g., James Love & Sean Finn, CPTech, Legal and Policy Issues
Concerning Parallel Trade (aka Re-Importation) of Pharmaceutical Drugs in the United
States, http://www.cptech.org/ip/fsd/love03312004.pdf.
88 See Office of the United States Global AIDS Coordinator, The President's
Emergency Plan for AIDS Relief (PEPFAR), U.S. Five Year Global HIVIAIDS Strategy
(2004), http://www.state.gov/documents/organization/2983 I.pdf.
89 See Sarah Fisher Ellison et al., Characteristics of Demand for pharmaceutical
products: an examination of four cephalosporins, 28(3) RAND J. ECON 426, 426-46
(1997) (demonstrating the demand elasticity of pharmaceutical products on the
dispensary side, as opposed to the prescription side, of drug prescriptions).
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acute detrimental personal effects, such as addiction or other
harms to the user, increased drug consumption is by itself unlikely
to have negative social consequences.9" Misuse of antimicrobials,
however, is of concern to the entire community, as one user's
misuse is unlikely to cause significant harm to that user, but on the
aggregate such misuse will contribute to hastening the
obsolescence of the misused antimicrobial.
There are two separate avenues where parallel imports and
other price mitigation measures can create and enhance problems
for antibiotic resistance. The first avenue is in the retardation of
research efforts, and the second is in the direct stimulation of
resistance by increasing consumption.
1. Research Effects
Retardation of research efforts is the worst possible effect
when new medicines need to come out to fight newly resistant
strains. Antibiotics, antivirals and other antimicrobials are an
extremely complicated class of medications. Currently, there are
many antibiotics available, but there are only about twelve classes
of antibiotics.9" Resistance to one member of a class does
occasionally indicate resistance to all members of that class, but
this is not always the case, and certain classes are more susceptible
to such deactivation.92 However, resistance to one member of a
class is often a harbinger of other related resistances, as slight
modifications of the resistance-conferring gene may grant
resistance to more than one, or all members of a class. 93
In antimicrobials, like all drugs, it is easier to build on past
research. That is, perhaps, one reason why there are so few
classes of antibiotics while there are hundreds of individual
90 With the most common drugs that are taken, such as acid-reflux medication,
cholesterol medication, and blood-pressure medication, addiction is not much of a
concern.
91 Sulfa antibiotics, P-Lactams (Penicillin), Tetracyclines, Macrolides (Erythromycin,
also includes the Lincosamides and Streptogramins), Aminoglycosides, Quinolones
(Cipro), Glycopeptides (Vancomycin), Rifampin, Nitroimidazoles (Flagyl),
Oxazolidinones (Linezolid-Zyvox), Cycloserine, and Aminocyclitols. See Wikipedia,
http://en.wikipedia.org/wiki/Antibiotic#endnote-antibiotics-classes-table.
92 Reservoirs of Antibiotic Use Resistance Network Bibliography, http://www.roar
project.org/.
93 Class resistance is a notable problem for P-lactams and the macrolides.
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antibiotics. The most recently approved new class of antibiotics,
the Oxazolidinones, was approved in 2000.9' It is the only new
antibiotic class to be introduced into a clinical setting in thirty
years. 95 By 2001, clinical resistance was observed.96 Within one
year of its introduction, the most advanced, cutting edge antibiotic,
had shown resistance.
Considering the historically slow speed of innovation in this
sector, and with antibiotic resistances arising so fast, any policy
which may have a negative impact on the speed of research in this
area must be carefully considered. Perhaps a total rethinking of
how antibiotic funding is handled is in order, similar to those
modifications proposed by James Love.97
2. Effects of Misuse
Though the negative effects on research which may result from
policies promoting equitable distribution may be substantial, they
present particularly difficult political and economic problems.
Additionally, they are likely not as severe as effects of misuse,
which are more tractable. If our ability to bring an antimicrobial
to clinical use is slowed from thirty to thirty-five years, it makes
little difference if the former antibiotics have been rendered
impotent in ten years.
Parallel imports are likely to increase the improper use of
antimicrobials by increasing both unnecessary consumption and
underconsumption. Unnecessary consumption will be increased
simply as a price effect and as medications can be shipped across
borders, due to the inherently designed lack of enforcement of
import controls.98 Underconsumption may increase as a secondary
effect of price, however, as underconsumption is likely a result of
patient capriciousness and the medications themselves; any effect
94 Daniel J. Diekema & Ronald N. Jones, Oxazolidinones: A Review, 59(1) DRUGS
7 (2000).
95 Health Protection Agency, In-vitro Activity of Oxazolidinone RWJ-416457 v.
linezolid-resistant and -susceptible staphylococci and enterococci,
http://www.phls.co.uk/srmd/div nsi-armrl/ARMRLposters/JJOXA.ppt.
96 Sotirios Tsiodras, Linezolid Resistance in a Clinical Isolate of Staphylococcus
Aureus, 358 LANCET 207 (2001).
97 See Love & Finn, supra note 87, and accompanying text.
98 See, e.g., Ellison et al., supra note 89.
N.C. J. INT'L L. & COM. REG.
from parallel imports is likely minor.
a. Unnecessary Consumption
Unnecessary consumption of antibiotics will only increase as
prices fall. Today, many antimicrobial drugs can be taken orally,
and so are relatively benign to take.99 Many powerful ones, like
Cipro and ketokonazole (an anti-fungal), are effective after only
one to three doses of medication.' ° If a patient approaches a
doctor with an illness that looks-at least to the patient-like an
antimicrobial will help, then the patient may request antibiotics.'0 '
It can often be more costly, in terms of patient time, reputation,
and perceived liability for a doctor to deny an unnecessary
antimicrobial.'0 2 If the costs go down, then the balance of power
shifts more toward the requesting patient.
Another, more substantial, concern that parallel imports raise
is the ability of patients to order medications from pharmacies and
suppliers located outside their nation.0 3 Today, one can reach
nearly every business by either international telephone, or, more
likely, by the Internet. 0' 4 For example, Great Britain allows
pharmacies to ship medications to individuals located outside of
Great Britain and who are not British citizens.105 Some opponents
of parallel imports have attacked parallel imports on this front by
99 In an interview with the New York Times, Alexander Flemming explicitly
mentioned the problem that oral medications could eventually cause: "But the public will
demand a preparation which can be taken by mouth, and doubtless they will get it. Then
will begin an era of self-medication with penicillin, with all its abuses." Penicillin's
Finder Assays Its Future, N.Y. TIMES, June 26, 1945, at 21.
100 Doctorfungus.org, http://www.doctorfungus.org/thedrugs/Ketoconazole.htm.
101 See James Sargent & H. Gilbert Welch, Reducing "Unnecessary" Antibiotic Use
in Primary Care: Hard Rules, Soft Calls, 4 EFFECTIVE CLINICAL PRAC. 136, 136-37
(2001).
102 See id. at 137 (stating that a medical practitioner may spend more time to
dissuade a patient from antibiotics).
103 See, e.g., Michelle Meadows, Imported Drugs Raise Safety Concerns (Sep.-Oct.
2002), http://www.fda.gov/fdac/features/2002/502-import.html.
104 See, e.g., Quality Health Inc.: Medicines for the Modem Mainstream, http://
www.qhi.co.uk.
105 For example, Quality Health Incorporated will sell several prescription drugs
(though none are antibiotics in this case) to overseas customers without prescription. See
[Vol. 31
2006] PARALLEL IMPORTS AND ANTIMICROBIAL RESISTANCE 841
claiming that foreign drugs or suppliers are somehow unsafe. 10 6
However, considering that the manufacturing of most on-patent
drugs are tightly controlled by their manufacturer, this argument
loses some credibility. A possible countervailing solution could
include labels containing different warnings, depending on the
rules of the regulatory apparatus of the jurisdiction from which the
drugs are purchased. Although some warnings and directions are
not written in English, this is easily remedied by the patient's
access to the Internet.
10 7
These two concerns need to be addressed separately, though
each is simple to address. To address the potential increase in
improper prescriptions issued by medical practitioners, countries
that allow parallel imports of antibiotics should implement
stronger policies regulating the prescription of all antibiotics,
instead of regulating the cutting edge antibiotics as is common
practice today.'08
Research has shown that educating both medical practitioners
and the public can help to stem this problem.'0 9 Education of both
groups, as well as institutional regulations-with appropriate
sanctions for unobservant doctors-should help to minimize
improper prescription of antibiotics." Fortunately, as both of
these methods are in place, at least in the United States and
Europe, merely extending these policies by linking them with
policy of parallel imports should be sufficient to rein in this
category of misuse.
More complicated, however, is the purchasing of drugs from
overseas pharmacies, when the exporting jurisdiction does not
require a prescription for the export, or where the pharmacies can
easily avoid what regulations do exist."' In these cases, parallel
importing jurisdictions should require that all imported medication
106 See, e.g., Meadows, supra note 103.
107 Package inserts and warnings for many drugs sold in the United States are
available at several sites on the internet. See, e.g., DruglnfoNet.com, http://www.
druginfonet.coml.
108 See, e.g., Cornell University, Institutional Antimicrobial Control Program
Restrictions, http://www-users.med.cornell.edu/-spon/picu/referenc/abxrestr.htm.
109 See Avorn & Solomon, supra note 63, at 128.
110 Id. at 130-33.
111 See, e.g., Quality Health, Inc., supra note 104.
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be screened by the respective border control agency, and every
prescription drug matched with a valid prescription. If an
individual attempts to obtain a drug from a foreign jurisdiction,
particularly an antimicrobial, without a valid prescription, then the
offending materials should be seized and, perhaps, donated to
medical dispensaries that serve poorer communities.12 With
today's computer technology, this should not be a complicated
task. Smuggling may be an issue. However, since these are not
addictive drugs, the leakage through the black market should be
minimal as long as the hassles imposed on the black market are
sufficient to raise those prices significantly above the legal market.
Tracking imported medications may also result in other
benefits. The risk of unsafe medications from foreign sources,
particularly Canada and the European Union, is hard to estimate. " 3
If a particular foreign dispensary is found to be distributing a
contaminated batch of medication, antimicrobial or otherwise,
potential victims could be quickly discovered, and medications in
transit could be intercepted prior to affecting the purchaser.
Of course, such tracking also implicates privacy issues, as
knowledge of the medications a particular individual is taking can
inform an interested party, or the government of the medical
condition of the individual. Such tracking is necessary in order
to properly monitor the import traffic in medications, such that
no medication enters without a valid prescription. Perhaps the
technology can be constructed such that names are concealed from
the screening personnel. However, since direct examination of the
individual pill bottles may be necessary, individuals wishing to
take advantage of parallel import restrictions may be required to
accept a potential decrease in privacy to realize the lower prices.
If privacy is an overriding issue, then an individual can always
purchase the medication from domestic sources.
A third method which would eliminate both the problems
inherent in uncontrolled direct-to-consumer purchases of drugs,
and the privacy concerns, would be a total ban on direct-to-
consumer shipment of medication from foreign sources. If an
112 Of course, the recipient organizations must have regulations and good practices
to prevent doctor misuse.
113 Kristina M. Lybecker, Economics of Reimportation and Risks of Counterfeit
Pharmaceuticals, 13(3) MANAGED CARE 1, 10-14 (2004).
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individual wishes to take advantage of parallel import pricing, then
the individual would need to approach a domestic dispensary,
which would then handle the foreign procurement. All medication
shipments would be business-to-business, and therefore domestic
controls on dispensaries and pharmacies would be left in place to
restrict consumer abuse. Although this solution may be attractive,
the privacy of international mail may limit its applicability. An
active legal direct-to-consumer market would likely limit all
but the most persistent avoiders. This may prove to be the
more practicable solution, as government oversight costs and
prescription validation can be placed on private industry. Direct-
to-consumer sales could still be conducted, with the consumer
shopping foreign dispensaries, but the medications are funneled
through the foreign dispensary's domestic affiliate for validation.
Other research on limiting antibiotic overuse focuses on the
removal of subsidization for Canadian consumers.114 However,
this policy, which increases the effective price that consumers pay
for the medication, significantly reduced consumption. Therefore,
it is incompatible with the price reduction purpose of parallel
imports. 115
Another proposed solution involves the grant of long term
patent rights over antibiotics, perhaps even permanent rights.
16
Proponents of such a solution urge that antibiotics are akin to
depleteable resources, similar to mineral deposits." 7  However,
antibiotics may be renewable resources, like trees. By creating a
unitary and monopolistic owner over specific antibiotics, the
owner has the incentive to rationally and beneficially utilize the
resource. " 8 In an ideal situation, this may function. However,
considering that the current system of limited patent protection is
114 See Deborah Marshall et al., Impact of Administrative Restrictions on Antibiotic
Use and Expenditure in Ontario: Time Series Analysis, 11 J. HEALTH SERV. RES. &
POL'Y 12, 12-20 (Jan. 2006).
115 Id. The data in this study show that total prescriptions for fluroquinolones
decreased, however, other antibiotics were substituted for the decrease in
fluroquinolones, though at a lower rate, resulting in a net decrease in antibiotic use. See
id.
116 Eric Kades, Preserving a Precious Resource: Rationalizing the Use of
Antibiotics, 99 Nw. U. L. REV 613 (2005).
117 Id. at 629.
118 Id. at 644-45.
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opposed by many in the political and heath care industries, the
political incentives are arrayed so deeply against this type of
system as to render it impracticable.
b. Underconsumption
When the responsibility for administration of a drug is
placed in the hands of the consumer, little can be done about
underconsumption. The best hope is to design drugs that are so
effective as to provide little chance for misuse. Drugs such as
Cipro and Ketoconazole, which require only a few days of dosing,
are best. Though side effects may occur, it is likely that the
medication will be taken for such a short time.
As resistance mounts, however, longer dosing schedules may
be required. If the dosing requirements are such that long term use
is required, especially when the drugs have significant side effects,
the power to ensure that the medication courses are taken to
completion is tremendously lessened. For specific problem
diseases, such as multi-drug resistant tuberculosis, measures as
strong as observed dosing are used. However these measures are
too invasive for the vast majority of uses.
While the price reductions wrought by parallel imports may
increase the likelihood that patients will be more willing to discard
future courses of antimicrobials, since patients are apparently quite
willing to discard future courses now, it is not clear that a price
reduction will significantly increase this. The best way to
minimize these problems is with education and by designing the
drugs to need a minimum of doses, so that consumers are not
inclined to skip future doses.
IV. Conclusion
The creation of legally sanctioned parallel imports in
medications may improve the ability for the poor to afford access
to needed medications and lower health care costs for society as a
whole. Though most attention to the potential drawbacks of
parallel imports focuses on the potential for the retardation of
future research, the effects of the policies on microbial resistance
cannot be ignored. Because antimicrobial misuse is related, in
large part, to patient access to the medications, an increase in non-
price based restrictions on the use of antimicrobials incorporated
into parallel import policies and legislation may be able to offset
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any increase in misuse as well as the concomitant increase in
antimicrobial resistance.
846 N.C.J. INT'L L. & CoM. REG. [Vol. 31
